Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology

GlobeNewsWire • Dec 8, 2025

Sana Biotechnology, Inc. (SANA) Presents at Evercore 8th Annual Healthcare Conference Transcript

Sana Biotechnology, Inc. (SANA) Presents at Evercore 8th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 3, 2025

Sana Biotechnology, Inc. (SANA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Sana Biotechnology, Inc. (SANA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 2, 2025

Sana Biotechnology to Present at December 2025 Investor Conferences

SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

GlobeNewsWire • Nov 24, 2025

Top 3 Genomics Stocks to Consider for Your Portfolio

Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.

Zacks Investment Research • Nov 18, 2025

All You Need to Know About Sana (SANA) Rating Upgrade to Buy

Sana (SANA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Nov 12, 2025

Sana Biotechnology: A Big Winner In Waiting? Maybe, But It Won't Happen Overnight

Sana Biotechnology, Inc. surged after hedge fund manager Eric Jackson called it a potential "100-bagger" due to its pioneering diabetes cell therapy. Sana Biotechnology's breakthrough islet cell therapy, using proprietary hypoimmune technology, enabled insulin production in a type 1 diabetes patient without immunosuppression. Significant challenges remain: scalable cell manufacturing, safe and scalable administration, and massive funding needs before commercial viability is achieved.

Seeking Alpha • Oct 16, 2025

Sana Biotechnology: Scope Goes Beyond HIP-Modified Pancreatic Islet Cells For T1D

Sana Biotechnology, Inc. remains a Strong Buy, driven by progress in HIP-modified cell therapies for Type 1 Diabetes and B-cell-mediated disorders. Sana Biotechnology's HIP-modified islet cell therapy showed a 6-month insulin response without needing immunosuppression in one T1D patient, supporting a paradigm shift in treatment. Upcoming 2025 data readouts from phase 1 GLEAM (SC291, autoimmune disorders) and VIVID (SC262, B-cell malignancies) trials are key catalysts for Sana Biotechnology.

Seeking Alpha • Oct 16, 2025

Sana Biotech Stock — The Next '100-Bagger'?

Sana Biotechnology, Inc. (NASDAQ:SANA) shares soared on Wednesday after outspoken stock promoter Eric Jackson named it as his latest potential “100-bagger.”

Benzinga • Oct 15, 2025

Sana Biotechnology, Inc. (SANA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sana Biotechnology, Inc. (NASDAQ:SANA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 11:30 AM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst Well, hello, everyone. I'm Maxwell Skor, biotech analyst with Morgan Stanley.

Seeking Alpha • Sep 8, 2025